These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31914238)

  • 1. Abuses of FDA Regulatory Procedures - The Case of Suboxone.
    Haffajee RL; Frank RG
    N Engl J Med; 2020 Feb; 382(6):496-498. PubMed ID: 31914238
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018.
    Barenie RE; Sinha MS; Kesselheim AS
    Value Health; 2021 Feb; 24(2):182-187. PubMed ID: 33518024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic Drug Policy and Suboxone to Treat Opioid Use Disorder.
    Haffajee RL; Frank RG
    J Law Med Ethics; 2019 Dec; 47(4_suppl):43-53. PubMed ID: 31955697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reforming the Orphan Drug Act for the 21st Century.
    Sarpatwari A; Kesselheim AS
    N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
    [No Abstract]   [Full Text] [Related]  

  • 5. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
    Yang YT; Chen B; Bennett CL
    J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.
    Khullar D; Ohn JA; Trusheim M; Bach PB
    N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697
    [No Abstract]   [Full Text] [Related]  

  • 7. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

  • 8. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
    Feldman R; Wang C
    N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
    [No Abstract]   [Full Text] [Related]  

  • 9. Congress, the FDA, and the fair development of new medications for children.
    McKinney RE
    Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
    [No Abstract]   [Full Text] [Related]  

  • 10. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 11. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 12. Orphan products: an emerging trend in drug approvals.
    Coté T; Kelkar A; Xu K; Braun MM; Phillips MI
    Nat Rev Drug Discov; 2010 Jan; 9(1):84. PubMed ID: 20043031
    [No Abstract]   [Full Text] [Related]  

  • 13. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 15. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 16. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ
    Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
    [No Abstract]   [Full Text] [Related]  

  • 17. New products highlight ambiguity of orphan drug law.
    Reid B
    Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 19. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-74. PubMed ID: 28252887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.